The POG project, led by Drs. Marco Marra and Janessa Laskin, integrates new technologies with whole genome and transcriptome analysis (WGTA) to advance precision cancer medicine. However, WGTA faces challenges such as low tumor material recovery from biopsies, low tumor content samples, and the cellular heterogeneity of tumors, which can hinder the identification of therapeutic targets. To overcome these limitations, we are assembling a cohort of POG samples for single-nucleus multi-omics analysis alongside standard WGTA, with an initial focus on low tumor content non-small cell lung cancers and cases with longitudinal biopsies. This approach will determine whether single-nucleus multi-omics expands the pool of suitable patient materials and improves eligibility for precision cancer treatments.
Single nucleus multi-omics for precision cancer genomic medicine
Canada’s Michael Smith Genome Sciences Centre respectfully acknowledges that we operate on the traditional, ancestral and unceded territories of the xʷməθkwəy̓əm (Musqueam), Səl̓ílwətaʔ/Selilwitulh (Tsleil-Waututh), and Skwxwú7mesh (Squamish) nations who have cared and nurtured this land for all time. We give thanks, as uninvited guests, to be able to live and work on these lands.
